---
document_datetime: 2024-05-22 12:37:08
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aripiprazole-mylan-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aripiprazole-mylan-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5103921
conversion_datetime: 2025-12-21 19:36:35.520499
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aripiprazole Mylan Pharma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0024/G            | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms | 17/05/2024                          |                                             | SmPC, Labelling and PL           |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |             | B.II.e.5.a.2 - Change   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------|
| IB/0023 | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/02/2024 |            | SmPC and PL |                         |
| N/0022  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 06/09/2023 |            | PL          |                         |
| WS/2306 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                  | 15/12/2022 | n/a        |             |                         |
| IB/0021 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/09/2022 | 09/10/2023 | SmPC and PL |                         |

<div style=\"page-break-after: always\"></div>

|           | - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | product new the   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| IA/0019   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                  | 22/06/2022 | n/a        |                        |                   |
| N/0018    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 03/05/2022 | 09/10/2023 | PL                     |                   |
| T/0017    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/09/2021 | 19/11/2021 | SmPC, Labelling and PL |                   |
| IB/0016/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/09/2021 | 19/11/2021 | SmPC and PL            |                   |

<div style=\"page-break-after: always\"></div>

| IB/0015   | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                          | 26/10/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 11/06/2020   | 18/11/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                         |
| R/0013    | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 12/12/2019   | 25/02/2020 | SmPC, Annex II and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Aripiprazole Mylan Pharma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0012   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                  | 07/11/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                                         |
| IB/0011   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/06/2019   | 25/02/2020 | SmPC and PL                      |                                                                                                                                                                                                                                                                                         |
| N/0010    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 13/03/2019   | 25/02/2020 | PL                               |                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 02/02/2018   | 14/02/2019   | SmPC, Labelling and PL   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| IB/0008   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                  | 16/06/2017   | 26/07/2017   | Annex II and PL          |
| IB/0007   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 15/12/2016   | 26/07/2017   | SmPC, Labelling and PL   |
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 10/08/2016   | 26/07/2017   | SmPC, Labelling and PL   |
| T/0005    | Marketing Authorisation Transfer from Pharmathen S.A to Mylan S.A.S. Transfer of Marketing Authorisation                                                                                                                                                       | 27/06/2016   | 01/08/2016   | SmPC, Labelling and PL   |
| IAIN/0004 | A.2.a - Administrative change - Change in the                                                                                                                                                                                                                  | 03/06/2016   | 01/08/2016   | SmPC,                    |

<div style=\"page-break-after: always\"></div>

|             | (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            | Labelling and PL                 |         |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------|
| IB/0001/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 23/03/2016 | 01/08/2016 | SmPC, Annex II, Labelling and PL | the MAH |
| IAIN/0003   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/03/2016 | n/a        |                                  |         |
| IAIN/0002/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                             | 16/03/2016 | 01/08/2016 | SmPC, Labelling and PL           |         |

<div style=\"page-break-after: always\"></div>

| B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|